High placebo response damages Lexicon's arthritis ambitions
This article was originally published in Scrip
Executive Summary
A high placebo response in a Phase II trial of Lexicon Pharmaceuticals' oral rheumatoid arthritis drug candidate has put a dent in US firm's ambitions for the product.